Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9870201 | 0.83 | ALDH1A1 (0.35) | — | |
| SCHEMBL637345 | 0.72 | MEN1 (0.43) | — | |
| SCHEMBL5595305 | 0.71 | KDM4E (0.52) | — | |
| SCHEMBL6247283 | 0.70 | KDM4E (0.41) | — | |
| SCHEMBL78634 | 0.70 | RAB9A (0.44) | — | |
| SCHEMBL4099996 | 0.70 | ALDH1A1 (0.35) | — | |
| SCHEMBL2337134 | 0.70 | RAB9A (0.51) | — | |
| SCHEMBL17048404 | 0.69 | — | — | |
| SCHEMBL115772 | 0.69 | NPC1 (0.34) | — | |
| SCHEMBL467414 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703387-B2 | STYRYLBENZODIAZEPINES | HOFFMANN-LA ROCHE INC. | 2004-03-09 | — | — | US | claimed |
| US-6703387-B2 | STYRYLBENZODIAZEPINES | HOFFMANN-LA ROCHE INC. | 2004-03-09 | — | — | US | disclosed |
| EP-1299364-A1 | BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-09 | — | — | EP | disclosed |
| US-20020128262-A1 | Inhibitors of HPV E1 helicase enzyme | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-09-12 | — | — | US | disclosed |
| WO-2002000632-A1 | BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128262-A1 | Inhibitors of HPV E1 helicase enzyme | DHX15, DHX35, DHX36 | NTRK1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.